Lucentis Faces Additional Pressure From NIH’s Avastin Trials
Executive Summary
Genentech could face difficulties enrolling trials for its ocular vascular endothelial growth factor inhibitor Lucentis due to pressure from NIH-sponsored trials of the firm's oncologic VEGF inhibitor Avastin
You may also be interested in...
Comparative Effectiveness: Managed Care Eager For Data, Including Cost
Traditional studies, such as randomized controlled clinical trials, post-marketing surveillance and monitoring, and voluntary reporting systems are not providing enough information about efficacy and safety of medications for health plans to make informed decisions, said participants in a panel on comparative effectiveness at an Academy of Managed Care Pharmacy meeting in Orlando in April
Comparative Effectiveness: Managed Care Eager For Data, Including Cost
Traditional studies, such as randomized controlled clinical trials, post-marketing surveillance and monitoring, and voluntary reporting systems are not providing enough information about efficacy and safety of medications for health plans to make informed decisions, said participants in a panel on comparative effectiveness at an Academy of Managed Care Pharmacy meeting in Orlando in April
Genentech Continues Pipeline Push After Rituxan Fizzles In PPMS
The failure of Genentech's Rituxan in a Phase II/III trial in primary progressive multiple sclerosis adds weight to the idea that B cells do not play a role in the disease and may cast doubt on rituximab's potential in lupus